Trimetazidine and reduction in mortality and hospitalization in patients with ischemic dilated cardiomyopathy: A post hoc analysis of the Villa Pini d'Abruzzo trimetazidine trial

Journal of Cardiovascular Pharmacology

Volumn 50, Issue 5, 2007, Pages 585-589

  Napoli, Pericle Di ^a,c   Giovanni, Paolo Di ^a   Gaeta, Marta Assunta ^a   Taccardi, Alfonso A ^a   Barsotti, Antonio ^b  

^a Casa di Cura Villa Pini d'Abruzzo   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c Dipartimento di Cardiologia UTIC   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

TRIMETAZIDINE;

AGED; ARTICLE; CLINICAL EXAMINATION; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONGESTIVE CARDIOMYOPATHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ECHOCARDIOGRAPHY; FEMALE; FUNCTIONAL STATUS; HAZARD RATIO; HEADACHE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MORTALITY; OPEN STUDY; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE;

AGED; C-REACTIVE PROTEIN; CARDIOMYOPATHY, DILATED; ECHOCARDIOGRAPHY; EXERCISE TEST; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; STROKE VOLUME; SURVIVAL RATE; TREATMENT OUTCOME; TRIMETAZIDINE; VASODILATOR AGENTS; VENTRICULAR FUNCTION, LEFT; WALKING;

EID: 36349008130     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31814fa9cb     Document Type: Article

References (27)

1. Bleumink GS, Knetsch AM, Sturkenboom MC, et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure. Eur Heart J. 2004;25:1614-1619.
2. Jessup M, Brozena S. Heart failure. N Engl J Med. 2003;348:2007-2018.
3. Mann D. Mechanism and models in heart failure: a combinatorial approach. Circulation. 1999;100:999-1008.
4. Kantor PF, Lucien A, Kozak R, et al. The antianginal drug Trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl Coenzyme A thiolase. Circ Res. 2000;86:580-588.
5. Lee L, Horowitz J, Frenneaux M. Metabolic manipulation in ischemic heart disease, a novel approach to treatment. Eur Heart J. 2004:25:634-641.
6. Sellier P. Chronic effects of trimetazidine on ergometric parameters in effort angina. Cardiovasc Drug Ther. 1990;4:822-823.
7. Detry JM, Sellier P, Pennaforte Cokkinos D, et al. Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Br J Clin Pharmacol. 1994;37:279-288.
8. Sharpe N. Cardiac remodelling in coronary artery disease. Am J Cardiol. 2004;93(Suppl):17B-20B.
9. Brottier L, Barat JL, Combe C, et al. Therapeutic value of a cardioprotective agent in patients with severe ischemic cardiomyopathy. Eur Heart J. 1990;11:207-212.
10. Fragasso G, Piatti PM, Monti L, et al. Short and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am Heart J. 2003;146:E18-E25.
11. Rosano GM, Vitale C, Sposato B, et al. Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease. a double-blind, placebo-controlled, study. Cardiovasc Diabetol. 2003;2:1-9.
12. Vitale C, Wajngaten M, Sposato B, et al. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J. 2004;25:1814-1821.
13. Di Napoli P, Taccardi AA, Barsotti A. Long-term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischemic dilated cardiomyopathy. Heart. 2005;91:161-165.
14. El-Kady T, El-Sabban K, Gabaly M, et al. Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunctional myocardium in ischemic cardiomyopathy: a 24-month study. Am J Cardiovasc Drugs. 2005;5:271-278.
15. Fragasso G, Palloshi A, Puccetti P, et al. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol. 2006;48:999-1000.
16. Allibardi S, Chierchia SL, Margonato V, et al. Effects of trimetazidine on metabolic and functional recovery of postischemic rat heart. Cardiovasc Drug Ther. 1998;12:543-549.
17. Renaud JF. Internal pH, Na+ and Ca++ regulation by trimetazidine during cardiac cell acidosis. Cardiovasc Drug Ther. 1988;1:677-686.
18. Ferrari R, Pepi P, Ferrari F, et al. Metabolic derangement in ischemic heart disease and its therapeutic control. Am J Cardiol. 1998;82:2K-13K.
19. Abbate A, Bussani R, Biondi-Zoccai GG, et al. Persistent infarct-related artery occlusion is associated with an increased myocardial apoptosis at post-mortem examination in humans late after an acute myocardial infarction. Circulation. 2002;106:1051-1054.
20. Fragasso G, Perseghin G, De Cobelli F, et al. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/ adenosine triphosphate ratio in patients with heart failure. Eur Heart J. 2006;27:942-948.
21. Guarnieri C, Muscari C. Effect of trimetazidine on mitochondrial function and oxidative damage during reperfusion of ischemic hypertrophied myocardium. Pharmacology. 1993;46:324-331.
22. Belardinelli R, Purcaro A. Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischemic cardiomyopathy. Eur Heart J. 2001;22:2164-2170.
23. Lu C, Dabrowski P, Fracasso G, et al. Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease: a double-blind, placebo-controlled, crossover study. Am J Cardiol. 1998;82:898-901.
24. Berton G, Cordiano R, Palmieri R, et al. C-reactive protein in acute myocardial infarction: association with heart failure. Am Heart J. 2003;145:1094-1101.
25. Alonso-Martinez JL, Llorente-Diez B, Echegaray-Agara M, et al. C-reactive protein as a predictor of improvement and readmission in heart failure. Eur J Heart Fail. 2002;4:331-336.
26. Williams FM, Tanda K, Kus M, et al. Trimetazidine inhibits neutrophil accumulation after myocardial ischemia and reperfusion in rabbits. J Cardiovasc Pharmacol. 1993;22:828-833.
27. Di Napoli P, Chierchia S, Taccardi AA, et al. Trimetazidine improves postischemic recovery by preserving endothelial nitric oxide synthase expression in isolated working rat hearts. Nitric Oxide. 2007;6:228-236.